Helix BioPharma Corp
HBP
Company Profile
Business description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Contact
40 Temperance Street
Suite 2700, Bay Adelaide Centre - North Tower
TorontoONM5H0B4
CANT: +1 604 684-2181
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,588.70 | 64.40 | 0.86% |
| CAC 40 | 6,927.12 | 347.83 | -4.78% |
| DAX 40 | 19,789.62 | 852.10 | -4.13% |
| Dow JONES (US) | 37,965.60 | 2,580.33 | -6.36% |
| FTSE 100 | 7,702.08 | 352.90 | -4.38% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 32,943.58 | 1,807.00 | 5.80% |
| NZX 50 Index | 11,887.54 | 111.66 | 0.95% |
| S&P 500 | 5,062.25 | 11.83 | -0.23% |
| S&P/ASX 200 | 7,401.30 | 58.00 | 0.79% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |